CL2016001983A1 - Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4 - Google Patents
Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4Info
- Publication number
- CL2016001983A1 CL2016001983A1 CL2016001983A CL2016001983A CL2016001983A1 CL 2016001983 A1 CL2016001983 A1 CL 2016001983A1 CL 2016001983 A CL2016001983 A CL 2016001983A CL 2016001983 A CL2016001983 A CL 2016001983A CL 2016001983 A1 CL2016001983 A1 CL 2016001983A1
- Authority
- CL
- Chile
- Prior art keywords
- receptor agonists
- muscarinic receptor
- aza compounds
- bicyclic aza
- compounds
- Prior art date
Links
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title abstract 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Abstract
<p>COMPUESTOS AZABICÍCLICOS, AGONISTAS DEL RECEPTOR MUSCARÍNICO M1 Y/O M4, ÚTILES EN EL TRATAMIENTO DE ENFERMEDADES TALES COMO ESQUIZOFRENIA, ADICCIONES, TRASTORNOS DEL MOVIMIENTO, ENTRE OTRAS Y COMPOSICION FARMACÉUTICA QUE LOS COMPRENDE.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1402013.5A GB201402013D0 (en) | 2014-02-06 | 2014-02-06 | Pharmaceutical compounds |
| GBGB1416622.7A GB201416622D0 (en) | 2014-09-19 | 2014-09-19 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001983A1 true CL2016001983A1 (es) | 2017-06-23 |
Family
ID=52465550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001983A CL2016001983A1 (es) | 2014-02-06 | 2016-08-05 | Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4 |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9670183B2 (es) |
| EP (3) | EP3406609B1 (es) |
| JP (7) | JP6479029B2 (es) |
| KR (1) | KR102352388B1 (es) |
| CN (2) | CN109851610B (es) |
| AU (3) | AU2015213900B2 (es) |
| BR (1) | BR112016017979B1 (es) |
| CA (1) | CA2938169C (es) |
| CL (1) | CL2016001983A1 (es) |
| CY (1) | CY1120834T1 (es) |
| DK (2) | DK3102568T3 (es) |
| ES (2) | ES2986327T3 (es) |
| FI (1) | FI3406609T3 (es) |
| HR (2) | HRP20241145T1 (es) |
| HU (1) | HUE068301T2 (es) |
| IL (1) | IL247117B (es) |
| LT (2) | LT3406609T (es) |
| MX (2) | MX371529B (es) |
| NZ (1) | NZ723103A (es) |
| PH (1) | PH12016501570A1 (es) |
| PL (2) | PL3102568T3 (es) |
| PT (2) | PT3102568T (es) |
| RS (2) | RS57843B1 (es) |
| RU (1) | RU2685230C2 (es) |
| SA (1) | SA516371614B1 (es) |
| SG (1) | SG11201606269WA (es) |
| SI (2) | SI3102568T1 (es) |
| SM (1) | SMT202400446T1 (es) |
| UA (1) | UA122121C2 (es) |
| WO (1) | WO2015118342A1 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014KN01075A (es) | 2011-11-18 | 2015-10-09 | Heptares Therapeutics Ltd | |
| ES2702182T3 (es) | 2013-03-15 | 2019-02-27 | Verseon Corp | Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa |
| SMT202400446T1 (it) * | 2014-02-06 | 2024-11-15 | Nxera Pharma Uk Ltd | Composti aza biciclici come agonisti del recettore muscarinico |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| BR112017004704A2 (pt) | 2014-09-17 | 2018-01-23 | Verseon Corp | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo |
| SG11201706411YA (en) * | 2015-02-27 | 2017-09-28 | Verseon Corp | Substituted pyrazole compounds as serine protease inhibitors |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| ES2789756T3 (es) | 2015-12-23 | 2020-10-26 | Merck Sharp & Dohme | Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4 |
| EP3478679B1 (en) * | 2016-07-01 | 2021-04-21 | Pfizer Inc. | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| EP3643703A4 (en) | 2017-06-21 | 2020-12-23 | Daiichi Sankyo Co., Ltd. | EP300 / CREBBP INHIBITOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| CN110944999A (zh) * | 2017-08-01 | 2020-03-31 | 勃林格殷格翰国际有限公司 | 中间体化合物和方法 |
| US10501483B2 (en) | 2017-10-24 | 2019-12-10 | Allergan, Inc. | Enamines and diastereo-selective reduction of enamines |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| AR115015A1 (es) * | 2018-03-23 | 2020-11-18 | Pfizer | Derivados de azaespiro piperazina |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| PE20221453A1 (es) | 2019-10-09 | 2022-09-21 | Novartis Ag | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
| AR120169A1 (es) * | 2019-10-09 | 2022-02-02 | Novartis Ag | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 |
| EP4069367B1 (en) | 2019-12-06 | 2024-05-15 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| AR121260A1 (es) * | 2020-02-05 | 2022-05-04 | Neurocrine Biosciences Inc | Antagonistas del receptor muscarínico 4 y métodos de uso |
| US11912705B2 (en) * | 2020-08-20 | 2024-02-27 | The Corporation Of Mercer University | Cathinone derivatives, pharmaceutical formulations, and methods |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| EP4663190A2 (en) | 2022-08-04 | 2025-12-17 | Nxera Pharma UK Limited | Muscarinic receptor agonists |
| CN120344513A (zh) * | 2022-09-16 | 2025-07-18 | 赛尔维治疗有限责任公司 | M4活化剂/调节剂及其用途 |
| EP4649077A1 (en) * | 2023-01-12 | 2025-11-19 | Cerevel Therapeutics, LLC | Spiro derivatives as m4 activators/modulators and uses thereof |
| CN120569376A (zh) | 2023-01-24 | 2025-08-29 | 纽罗克里生物科学有限公司 | 氘代化合物 |
| CN116496195A (zh) * | 2023-05-10 | 2023-07-28 | 南京优氟医药科技有限公司 | 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法 |
| WO2025030095A1 (en) | 2023-08-03 | 2025-02-06 | Neurocrine Biosciences, Inc. | Methods of synthesis |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| WO1999032489A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| US7164024B2 (en) * | 2001-04-20 | 2007-01-16 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
| JP2008501031A (ja) * | 2004-05-28 | 2008-01-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| EP1863490A2 (en) * | 2005-03-28 | 2007-12-12 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
| RU2008130094A (ru) | 2005-12-22 | 2010-01-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы мускариновых рецепторов |
| EP1988892A2 (en) | 2006-02-22 | 2008-11-12 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| ATE517106T1 (de) * | 2006-02-22 | 2011-08-15 | Vertex Pharma | Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren |
| CA2643267A1 (en) * | 2006-03-03 | 2007-09-20 | Novartis Ag | N-formyl hydroxylamine compounds |
| GB0706188D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| US8119661B2 (en) * | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| AU2009309988A1 (en) | 2008-10-29 | 2010-05-06 | Grunenthal Gmbh | Substituted spiroamines |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| TW201211028A (en) * | 2010-08-10 | 2012-03-16 | Dainippon Sumitomo Pharma Co | Fused ring pyrrolidine derivatives |
| IN2014KN01075A (es) * | 2011-11-18 | 2015-10-09 | Heptares Therapeutics Ltd | |
| BR112015006029B1 (pt) * | 2012-09-18 | 2022-01-25 | Heptares Therapeutics Limited | Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias |
| HK1214815A1 (zh) | 2013-04-30 | 2016-08-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Zeste增强子同源物2的抑制剂 |
| AR099312A1 (es) | 2014-02-06 | 2016-07-13 | Riboscience Llc | Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza |
| JP6495929B2 (ja) | 2014-02-06 | 2019-04-03 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイルピロールアミド誘導体およびｂ型肝炎の治療のための医薬としてのその使用 |
| SMT202400446T1 (it) * | 2014-02-06 | 2024-11-15 | Nxera Pharma Uk Ltd | Composti aza biciclici come agonisti del recettore muscarinico |
| US10350206B2 (en) | 2014-09-19 | 2019-07-16 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as BUB1 inhibitors |
| KR20170054508A (ko) | 2014-09-19 | 2017-05-17 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 신규 가용성 구아닐레이트 시클라제 활성화제 및 그의 용도 |
| PT3733662T (pt) | 2014-09-19 | 2023-08-18 | Forma Therapeutics Inc | Derivados piridin-2(1h)-ona-quinolinona como inibidores de isocitrato desidrogenase mutante |
-
2015
- 2015-02-06 SM SM20240446T patent/SMT202400446T1/it unknown
- 2015-02-06 HR HRP20241145TT patent/HRP20241145T1/hr unknown
- 2015-02-06 CN CN201910003375.6A patent/CN109851610B/zh active Active
- 2015-02-06 EP EP18179258.1A patent/EP3406609B1/en active Active
- 2015-02-06 NZ NZ723103A patent/NZ723103A/en unknown
- 2015-02-06 LT LTEP18179258.1T patent/LT3406609T/lt unknown
- 2015-02-06 LT LTEP15703826.6T patent/LT3102568T/lt unknown
- 2015-02-06 US US15/117,018 patent/US9670183B2/en active Active
- 2015-02-06 FI FIEP18179258.1T patent/FI3406609T3/fi active
- 2015-02-06 EP EP24177415.7A patent/EP4413985A3/en active Pending
- 2015-02-06 UA UAA201609185A patent/UA122121C2/uk unknown
- 2015-02-06 EP EP15703826.6A patent/EP3102568B1/en active Active
- 2015-02-06 MX MX2016010322A patent/MX371529B/es active IP Right Grant
- 2015-02-06 PL PL15703826T patent/PL3102568T3/pl unknown
- 2015-02-06 HR HRP20181499TT patent/HRP20181499T1/hr unknown
- 2015-02-06 CA CA2938169A patent/CA2938169C/en active Active
- 2015-02-06 RS RS20181127A patent/RS57843B1/sr unknown
- 2015-02-06 KR KR1020167024572A patent/KR102352388B1/ko active Active
- 2015-02-06 SI SI201530399T patent/SI3102568T1/sl unknown
- 2015-02-06 SI SI201532034T patent/SI3406609T1/sl unknown
- 2015-02-06 AU AU2015213900A patent/AU2015213900B2/en active Active
- 2015-02-06 BR BR112016017979-0A patent/BR112016017979B1/pt active IP Right Grant
- 2015-02-06 JP JP2016550483A patent/JP6479029B2/ja active Active
- 2015-02-06 PL PL18179258.1T patent/PL3406609T3/pl unknown
- 2015-02-06 WO PCT/GB2015/050331 patent/WO2015118342A1/en not_active Ceased
- 2015-02-06 HU HUE18179258A patent/HUE068301T2/hu unknown
- 2015-02-06 RS RS20240960A patent/RS65894B1/sr unknown
- 2015-02-06 CN CN201580017993.6A patent/CN106458986B/zh active Active
- 2015-02-06 DK DK15703826.6T patent/DK3102568T3/en active
- 2015-02-06 SG SG11201606269WA patent/SG11201606269WA/en unknown
- 2015-02-06 ES ES18179258T patent/ES2986327T3/es active Active
- 2015-02-06 MX MX2020001236A patent/MX393637B/es unknown
- 2015-02-06 PT PT15703826T patent/PT3102568T/pt unknown
- 2015-02-06 RU RU2016133684A patent/RU2685230C2/ru active
- 2015-02-06 DK DK18179258.1T patent/DK3406609T3/da active
- 2015-02-06 ES ES15703826.6T patent/ES2688548T3/es active Active
- 2015-02-06 PT PT181792581T patent/PT3406609T/pt unknown
-
2016
- 2016-08-04 SA SA516371614A patent/SA516371614B1/ar unknown
- 2016-08-04 IL IL247117A patent/IL247117B/en active IP Right Grant
- 2016-08-05 CL CL2016001983A patent/CL2016001983A1/es unknown
- 2016-08-08 PH PH12016501570A patent/PH12016501570A1/en unknown
-
2017
- 2017-05-10 US US15/591,605 patent/US9926297B2/en active Active
-
2018
- 2018-02-22 US US15/902,537 patent/US10196380B2/en active Active
- 2018-09-27 CY CY181100996T patent/CY1120834T1/el unknown
- 2018-12-12 US US16/217,570 patent/US10385039B2/en active Active
-
2019
- 2019-02-01 JP JP2019017086A patent/JP6774513B2/ja active Active
- 2019-03-07 AU AU2019201579A patent/AU2019201579B2/en active Active
- 2019-07-01 US US16/459,179 patent/US10689368B2/en active Active
-
2020
- 2020-06-17 US US16/904,099 patent/US10961225B2/en active Active
- 2020-10-05 JP JP2020168341A patent/JP2021006571A/ja not_active Withdrawn
- 2020-11-26 AU AU2020277225A patent/AU2020277225A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060030A patent/JP7652829B2/ja active Active
- 2023-05-02 JP JP2023076025A patent/JP7652833B2/ja active Active
- 2023-05-02 JP JP2023076024A patent/JP7652832B2/ja active Active
-
2025
- 2025-03-14 JP JP2025041135A patent/JP2025085736A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001983A1 (es) | Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4 | |
| CL2015002125A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| MX2016012103A (es) | Agonistas del receptor muscarinico. | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| MX386752B (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| CO2019004945A2 (es) | Inhibidores de la magl | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CL2016000922A1 (es) | Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4 | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| CL2016001840A1 (es) | Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer. | |
| CL2015002222A1 (es) | Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos. | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CL2018003265A1 (es) | Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
| CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
| MX381313B (es) | Derivados de benzimidazol como moduladores de ror-gamma | |
| BR112016016158A2 (pt) | Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos | |
| CL2016003212A1 (es) | Derivados de indolín-2-ona o pirrolo-piridín-2-ona. | |
| UY36075A (es) | Derivados de tubulisina | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| CL2018001085A1 (es) | Derivados de indolin-2-ona | |
| CL2015002620A1 (es) | Derivados piridin-4-ilo | |
| SG10201908881PA (en) | Fused bicyclic compounds for the treatment of disease | |
| CL2016001024A1 (es) | Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades. |